[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]  Bhavneesh Sharma MBBS, MD, MBA (Finance) [@bs2537](/creator/twitter/bs2537) on x 7866 followers Created: 2025-07-21 18:30:35 UTC Long Cytokinetics, $CYTK. My analysis points to a $XX PT (+36% upside)-1 year timeframe. Thesis: Aficamten PDUFA: Dec 26, 2025. High probability of approval for oHCM. Superior Profile: Better efficacy & safety vs. $BMY's Camzyos. TAM Expansion: ACACIA trial in nHCM could unlock a ~$2B+ market. Funded: Cash runway through commercialization. #Biotech #Investing #Cardiology #PDUFA  XXXXX engagements  **Related Topics** [investment](/topic/investment) [$2b](/topic/$2b) [$bmys](/topic/$bmys) [superior](/topic/superior) [finance](/topic/finance) [sharma](/topic/sharma) [$cytk](/topic/$cytk) [Post Link](https://x.com/bs2537/status/1947363591167893642)
[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
Bhavneesh Sharma MBBS, MD, MBA (Finance) @bs2537 on x 7866 followers
Created: 2025-07-21 18:30:35 UTC
Long Cytokinetics, $CYTK. My analysis points to a $XX PT (+36% upside)-1 year timeframe.
Thesis: Aficamten PDUFA: Dec 26, 2025. High probability of approval for oHCM. Superior Profile: Better efficacy & safety vs. $BMY's Camzyos. TAM Expansion: ACACIA trial in nHCM could unlock a ~$2B+ market. Funded: Cash runway through commercialization. #Biotech #Investing #Cardiology #PDUFA
XXXXX engagements
Related Topics investment $2b $bmys superior finance sharma $cytk
/post/tweet::1947363591167893642